Watch CNBC's full interview with Merck CEO Rob Davis on $11.5 billion Acceleron acquisition

Merck CEO Rob Davis joins CNBC's Meg Tirrell to discuss the company's major acquisition of Acceleron Pharma valued at $11.5 billion and provides an update on Merck's highly anticipated Covid-19 pill.